CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2018--
Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present new
magnetic resonance imaging (MRI) data from the open-label extension
MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne
muscular dystrophy (DMD) at the American Academy of Neurology 70th
Annual Meeting to be held April 21 – 27, 2018, in Los Angeles, CA, at
the Los Angeles Convention Center.
Richard Finkel, M.D., Chief, Division of Neurology, Department of
Pediatrics at Nemours Children’s Health System and a Principal
Investigator for the study, will give an oral presentation titled
“MoveDMD®: Positive Effects of Edasalonexent, an NF-ĸB
Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy
in Phase 2 Study with an Open-Label Extension” during the S29 session
“Child Neurology and Developmental Neurology” on Wednesday, April 25,
2018 from 2:00pm – 2:12pm PT.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that
is being developed as a potential disease-modifying therapy for all
patients affected by DMD, regardless of their underlying mutation.
Edasalonexent inhibits NF-kB, a protein that is activated in DMD and
drives inflammation and fibrosis, muscle degeneration and suppresses
muscle regeneration. Edasalonexent continues to be dosed in the
open-label extension of the MoveDMD Phase 2 clinical trial and Catabasis
is preparing for a single global Phase 3 trial to evaluate the efficacy
and safety of edasalonexent for registration purposes, dependent on
raising capital. The FDA has granted orphan drug, fast track and rare
pediatric disease designations and the European Commission has granted
orphan medicinal product designation to edasalonexent for the treatment
of DMD. For a summary of clinical results reported to-date, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our SMART
(Safely Metabolized And Rationally Targeted) Linker drug discovery
platform enables us to engineer molecules that simultaneously modulate
multiple targets in a disease. Our lead program in development is
edasalonexent for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our pipeline of drug candidates, please
visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180418005043/en/
Source: Catabasis Pharmaceuticals, Inc.
Investor and Media Contact
Catabasis
Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
